title: Follow-up study of MS patients treated with high-dose intravenous methylprednisolone.
abstract: In a longitudinal prospective study, we followed 56 patients (17 men, 29 women) with definite multiple sclerosis (MS), who were treated with high-dose intravenous methylprednisolone (IVMP), 10 consecutive days with 1000 mg IVMP daily. Mean follow-up period after entry was 2.6 years (range 1.7-3.5 yrs). All patients were treated because of a symptomatic deterioration. Independent of the disease courses (RR-relapsing remitting/CP-chronic progressive/CP+RR- mixed course), 65% of the 46 MS patients (30/46) showed a clinical improvement after the first IVMP course, expressed by a decrease in the EDSS rating (1.0 point or more). During the follow-up period 59 additional IVMP courses (range 0-5 courses per patient) were given; 8 patients were treated with a combination of cyclophosphamide and prednisone, because of strong continuous progression. During the follow-up period 19 patients (41%) showed an increase in the EDSS-rating (1.0 point or more) compared with the EDSS level just after the first IVMP; 22 patients (48%) had no changes in the EDSS-rating, and 5 patients (11%) showed a clinical improvement (decrease of 1.0 point or more). In the relapsing MS patients (RR and CP+RR, n = 38) mean relapse rate/patient/year prior to the first IVMP was 2.6, which significantly (p < 0.0001) decreased to 0.8 during the follow-up period. Statistically no significant difference was found between baseline EDSS and EDSS ratings after the follow-up period in relapsing MS patients.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Neurology, University Hospital Nijmegen, The Netherlands.
authors: S T
authors: ST
authors: Frequin
authors: K J
authors: KJ
authors: Lamers
authors: F
authors: F
authors: Barkhof
authors: G F
authors: GF
authors: Borm
authors: O R
authors: OR
authors: Hommes
mesh_terms: D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins / Q000134:cerebrospinal fluid; D007262:Infusions, Intravenous; D008137:Longitudinal Studies; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D009460:Neurologic Examination / Q000187:drug effects; D043025:Oligoclonal Bands; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D012008:Recurrence
chemical_list: D007136:Immunoglobulins; D043025:Oligoclonal Bands; D003520:Cyclophosphamide; D011241:Prednisone; D008775:Methylprednisolone